Navigation Links
Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010
Date:10/19/2010

d quarter of 2010.  On a constant currency basis, international sales increased 2.1% in the third quarter of 2010, as a result of higher shipments of MedSurg Equipment partially offset by lower sales of Orthopaedic Implants.

Worldwide sales of Orthopaedic Implants were $1,029 million for the third quarter of 2010, representing an increase of 1.2%.  On a constant currency basis, sales of Orthopaedic Implants increased 1.3% in the third quarter of 2010, based on higher domestic sales of hips, knees, and trauma implant systems.

Worldwide sales of MedSurg Equipment were $739 million for the third quarter of 2010, representing an increase of 16.1%.  On a constant currency basis, sales of MedSurg Equipment increased 16.3% in the third quarter of 2010, based on higher shipments of surgical equipment and surgical navigation systems, endoscopic and communications systems and patient handling and emergency medical equipment as well as sales growth through acquisitions.  

Earnings Analysis Net earnings for the third quarter of 2010 included a gain of $13 million (net of income tax expense) as a result of the sale of the Company's Orthopaedic Implants manufacturing facility based in Caen, France.  In addition, during the third quarter of 2010, the Company recorded a favorable income tax expense adjustment of $7 million to reduce the income tax liability originally recorded in the fourth quarter of 2009 associated with the repatriation of foreign earnings to the United States.  Net earnings for the third quarter of 2009 were reduced by $48 million in restructuring charges (net of income tax benefits) related to decisions to terminate certain third party agent agreements, simplify some Company organizations and discontinue selling certain products.

Excluding the impacts of the 2010 gain on sale of assets and income tax adjustment as well as the 2009 restructuring charges described above, adjusted net earnings for the th
'/>"/>

SOURCE Stryker Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Strykers Biotech Division Receives FDA Warning Letter
2. Stryker Operating Results for Quarter Ended September 30, 2009
3. Stryker Biotech and its Top Management Indicted for Illegal Promotion of Medical Devices Used in Invasive Surgeries
4. Stryker Announces Change in Chairman of the Board of Directors
5. Stryker Modifies Its Dividend Policy and Declares Transition Dividend
6. Stryker to Host Analyst Meeting
7. Stryker Announces Agreements To Acquire Assets
8. Stryker Corporation Announces Pricing of Senior Notes
9. Stryker Updates Expected 2009 Results and Provides 2010 Outlook
10. Stryker Completes Acquisition of Ascent Healthcare Solutions
11. RoundTable Healthcare Partners Announces Sale of Ascent Healthcare Solutions to Stryker Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015  Legal-Bay LLC, The Lawsuit ... Boehringer Ingelheim Pharmaceuticals, is seeking FDA approval for ... According to PBR, Boehringer submitted a supplemental new ... that Pradaxa will be approved for the prophylaxis ... (PE) for patients who have undergone a primary ...
(Date:4/20/2015)... , April 20, 2015 Research published today ... of Sciences (PNAS) demonstrates that technology invented ... Casey Eye Institute can improve the ... Optical coherence tomography (OCT) angiography could largely replace ... diseases. OHSU researchers found that OCT ...
(Date:4/20/2015)... BILLERICA, Mass. , April 20, 2015 /PRNewswire/ ... tools for cell metabolism research, introduces the XFp ... a unique real-time assay on live cells that ... one-hour test measures both the mitochondrial and glycolytic ... values with metabolic activity under stressed conditions, induced ...
Breaking Medicine Technology:Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE 2Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE 3Study shows new technology may improve management of leading causes of blindness 2Study shows new technology may improve management of leading causes of blindness 3Study shows new technology may improve management of leading causes of blindness 4Study shows new technology may improve management of leading causes of blindness 5New XFp Cell Energy Phenotype Test Determines Metabolic Potential 2New XFp Cell Energy Phenotype Test Determines Metabolic Potential 3
... As previously announced, primary endpoint not met; ... with ERBITUX,-, NEW YORK, April 16, 2007 ... Company today,announced detailed results from the EPIC ... trial - comparing ERBITUX(R),(Cetuximab) plus irinotecan to ...
... WIRE)--Apr 17, 2007 - Curis, Inc.,(NASDAQ:CRIS), a ... primarily for cancer treatment, today announced that ... the 98th Annual Meeting,of the American Association ... also disclosed that its April 2005 discovery,collaboration ...
Cached Medicine Technology:Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 2Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 3Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 4
(Date:4/21/2015)... (PRWEB) April 21, 2015 The PracticeMatch ... from 5:00 to 8:00 pm at the William and Ida ... Hill, NC 27599. More than 50 hospitals, clinics and groups ... All specialties will be represented. Attendees will enjoy free hors ... Career Fairs for PracticeMatch says “Chapel Hill is ...
(Date:4/21/2015)... United Benefit Advisors (UBA), the nation’s ... to welcome Power Kunkle Benefits Consulting as its ... Jeff Power have been committed to providing the ... more than 450 clients. For Power Kunkle Benefits ... stewardship, ethical consulting, and measurable results. , ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Atlantic ... the launch of Medicare-Medicaid Dual Eligibles Database, a ... on care provided to the more than 9 ... account for more than $300 billion in annual ... – the same team that also creates the ...
(Date:4/21/2015)... Nashville, Tenn. – Radsource, a leader ... Archiving and Communication Systems (PACS), has expanded its ... the first quarter of 2015. , Kentucky Breast ... and Lowcountry Orthopaedics & Sports Medicine (Charleston, SC) ... services. Mt. San Rafael Hospital (Trinidad, CO) will ...
(Date:4/21/2015)... Timonium, Maryland (PRWEB) April 21, 2015 eSight ... who are legally blind to see and, on Tuesday, May ... (LVS of MD & VA) will host an unveiling ... Timonium, MD office. LVS of MD & VA will be ... eyewear. A limited number of individual patient demonstrations will be ...
Breaking Medicine News(10 mins):Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 2Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 3Health News:Power Kunkle Benefits Consulting Is the Latest Partner Firm To Join United Benefit Advisors 2Health News:New AIS Database Tracks All Programs, Plans Serving the Dual-Eligible Community 2Health News:Radsource Adds 4 ProtonPACS Clients in 1st Quarter 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 3
... Steps To Serve Your Champagne This Holiday With Style And ... Ease - And Most Importantly ... ,There,s nothing that brings a little sparkle to your holiday ... Americans will,consume more than 900 million glasses of champagne this ...
... Calif., Dec. 21 Pharmacyclics,Inc. (Nasdaq: PCYC ) ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of non-small cell lung cancer (NSCLC) patients ... combination with whole brain,radiation therapy (WBRT) was filed with ...
... 21 Biodel Inc. (Nasdaq:,BIOD) today announced that Dr. ... corporate update at the 26th Annual JPMorgan Healthcare,Conference on ... The JPMorgan Healthcare Conference will be held January ... Francisco, California., Interested parties may access a link ...
... Center receives shipment milestone - expanding, their depth ... SET technologies, IRVINE, Calif., Dec. 21 ... Read-Through Motion and Low,Perfusion pulse oximetry, today announced ... bedside pulse oximeter (excluding hand-held units) to,Alta Bates ...
... Contest Urges Young People to Promote Home,Safety, ... has named the winners of its 2008 National ... States Environmental Protection,Agency. First-place winner is Sara Garcia, ... Science in Hollywood, Florida; second-place winner is,Daniel Carr, ...
... Ireland Cancer Center of University Hospitals Case Medical Center, in ... the Cancer Research Network, found that the majority of older ... the standard of treatment five years of daily oral ... the February issue of Journal of Clinical Oncology and released ...
Cached Medicine News:Health News:Five Steps to Pop the Cork - Not Your Eye Out 2Health News:Five Steps to Pop the Cork - Not Your Eye Out 3Health News:Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases 2Health News:Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases 3Health News:Biodel Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 7th, 2008 2Health News:Biodel Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 7th, 2008 3Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 2Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 3Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 4Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 5Health News:National Safety Council Names Winners of Radon Poster Contest 2Health News:Ireland Cancer Center researcher finds standard treatment for breast cancer not followed 2
Aluminum english and metric ruler. 1 3/8 inche wide....
At 14 cm point, ruler is bent at 90 degrees angle brought to a blunt point at 15 cm....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: